Bristol-Myers Squibb Company (NYSE:BMY) is one of the best NYSE stocks to buy and hold for the next decade. On October 27, ...

Otezla (apremilast) is an oral tablet commonly used to treat psoriatic arthritis in adults. Psoriatic arthritis is a long-lasting condition that affects the joints in people with psoriasis. Common ...

Continuous improvement was observed across the different domains of minimal disease activity criteria with guselkumab. Patients with active psoriatic arthritis (PsA) were able to achieve continuous ...

UCB, a global biopharmaceutical company, today announced new three-year data from Phase 3 trials, and their open-label extensions, investigating BIMZELX (R) (bimekizumab-bkzx) in adults with active ...

Improvement in both joint and skin symptoms reinforce TREMFYA® as a first-line treatment option with a proven safety profile for adults with active psoriatic arthritis BARCELONA, June 11, 2025 ...

Objective To investigate the association between peripheral disease activity and pre-eclampsia, gestational hypertension, ...

We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. Patients with active PsA met disease control endpoints ...

TREMFYA® is now approved for pediatric patients living with moderate to severe plaque psoriasis, who are candidates for systemic therapy or phototherapy, and active psoriatic arthritis in children six ...

Infections. TREMFYA® may lower the ability of your immune system to fight infections and may increase your risk of infections. Your healthcare provider should check you for infections and tuberculosis ...

The safety of etanercept in this patient population was established through multiple pediatric trials, including a clinical study in 69 children aged 2 to 17 years with moderately to severely active ...

Psoriatic arthritis disease activity levels appear to increase on average during perimenopause before decreasing slightly ...

"Despite advancements in the treatment of pediatric plaque psoriasis and active psoriatic arthritis, there continues to be a significant gap in available therapies for these debilitating ...